Downloads: 118
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bcp.14354.pdf | 438.1 kB | Adobe PDF | View/Open |
Title: | Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation |
Authors: | Muranushi, Hiroyuki Kanda, Junya https://orcid.org/0000-0002-6704-3633 (unconfirmed) Arai, Yasuyuki https://orcid.org/0000-0002-9662-5093 (unconfirmed) Shindo, Takero https://orcid.org/0000-0002-2085-6151 (unconfirmed) Hishizawa, Masakatsu Yamamoto, Takashi Kondo, Tadakazu https://orcid.org/0000-0002-8959-6271 (unconfirmed) Yamashita, Kohei Matsubara, Kazuo Takaori-Kondo, Akifumi |
Author's alias: | 諫田, 淳也 新井, 康之 進藤, 岳郎 菱澤, 方勝 山本, 崇 近藤, 忠一 松原, 和夫 髙折, 晃史 |
Keywords: | cord blood transplantation drug monitoring mycophenolic acid |
Issue Date: | Dec-2020 |
Publisher: | wiley |
Journal title: | British Journal of Clinical Pharmacology |
Volume: | 86 |
Issue: | 12 |
Start page: | 2464 |
End page: | 2472 |
Abstract: | [Aims] We performed the retrospective analysis to clarify the significance of drug monitoring for mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), in prophylaxis for graft‐vs‐host disease (GVHD) in cord blood transplantation. [Methods] We retrospectively analysed the data of 46 patients who underwent first cord blood transplantation and received GVHD prophylaxis with tacrolimus plus MMF. MPA levels were measured on days 7 and 21, and 24‐hour areas under the curve (AUC0–24) were estimated. [Results] The engraftment and 3‐year overall survival rates of all patients were 94% and 78%, respectively. The cumulative incidence of sepsis before engraftment was higher in patients with AUC0–24 on day 7 of >60 μg h/mL than in other patients (33 vs 6%, P = .02). The cumulative incidence of grade II–IV acute GVHD was higher in patients with AUC0–24 on day 21 of ≤30 μg h/mL than in other patients (80 vs 50%, P = .04). The cumulative incidence of human herpesvirus 6 reactivation was higher in patients with AUC0–24 on day 21 of ≤48 μg h/mL (median) than in other patients (50 vs 19%, P = .03). [Conclusion Blood level of MPA was associated with risk of acute GVHD and infection. A prospective trial evaluating the benefit of personalized MMF dosing using MPA levels is needed. |
Rights: | This is the peer reviewed version of the following article: ['British Journal of Clinical Pharmacology', 86(12), 2464-2472], which has been published in final form at https://doi.org/10.1111/bcp.14354. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. The full-text file will be made open to the public on 30 May 2021 in accordance with publisher's 'Terms and Conditions for Self-Archiving'. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/259706 |
DOI(Published Version): | 10.1111/bcp.14354 |
PubMed ID: | 32386102 |
Appears in Collections: | Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.